Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Chong Kun Dang Pharmaceutical Corp. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio is distributed, with distinct art units and distinct examiners each handling 1 of the 3 pending office actions. This structure indicates that the company's pharmaceutical research covers several different technical niches, each subject to the review of a different specialized group.
WARD, PAUL V is the busiest examiner for the company, currently overseeing 1 pending office action. Since each examiner is responsible for a case, the company does not face a concentration of risk with any individual. However, this also means that the company cannot leverage experience with an examiner to predict outcomes for the other pending office actions. Practitioners should be prepared for separate prosecution tracks within the Biotechnology & Pharmaceuticals field, as the art units may have varying internal policies and timelines. The lack of overlap among the examiners requires a customized approach for each office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| ENGLISH, CONNOR KENNEDY | 1 | 59.3% | +50.3% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854489 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | VARADARAJ, ARCHANA | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | VARADARAJ, ARCHANA | 33d |
| 18286037 | 1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ENGLISH, CONNOR KENNEDY | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1625 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854489 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | WARD, PAUL V | 1622 | §112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18286037 | 1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | VARADARAJ, ARCHANA | 1658 | §102§103Other | Non-Final OA | 33d | Pending | Dec 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChong Kun Dang Pharmaceutical Corp. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Paul V Ward has the most, with 1 of Chong Kun Dang Pharmaceutical Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
